ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01 | VuMedi

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01

By 2024 ESMO Annual Meeting Insights Hub FEATURING Paolo Tarantino

By 2024 ESMO Annual Meeting Insights Hub FEATURING Paolo Tarantino

719 views

September 24, 2024

NATALEE Trial & Adjuvant Ribociclib Outcomes

00:00

DESTINY-Breast12: T-DXd in HER2-Positive Cancer

04:12

KEYNOTE-522: Pembrolizumab's Survival Impact

06:46

CAPitello-290: AKT Inhibition in TNBC

09:11

ICARUS-Breast01: HER3-DXd Efficacy & Safety

11:45

Comments 0

Login to view comments. Click here to Login